Bovine Prothrombin (Bos taurus)

Bovine prothrombin is a vitamin K-dependent zymogen derived from bovine (Bos taurus) blood plasma that serves as the precursor to thrombin, the serine protease enzyme responsible for converting fibrinogen to fibrin during coagulation. In supplement and laboratory contexts, it is primarily utilized as a PCR enhancer to suppress primer dimer formation rather than for documented human therapeutic benefit.

Origin & History

Bovine prothrombin is a serine protease precursor derived from cattle (Bos taurus) blood plasma, containing 14 exons and spanning approximately 15.4 kilobase pairs. It is produced through a conversion reaction where prothrombin is activated by tissue thromboplastin in the presence of calcium chloride to generate the active enzyme thrombin.

Historical & Cultural Context

The research contains no information about traditional or historical use of bovine prothrombin in any medicine system. Its documented use appears limited to modern laboratory applications.

Health Benefits

• No clinical health benefits documented - The provided research contains no human clinical trials or therapeutic studies
• Laboratory research application only - Used as a PCR enhancer to prevent primer dimer formation
• Theoretical coagulation support - Active form (thrombin) converts fibrinogen to fibrin for clot formation
• No evidence for supplement use - Research focuses solely on biochemical characterization
• No safety or efficacy data available - Lacks human trials for health applications

How It Works

Bovine prothrombin (Factor II) is a 72 kDa vitamin K-dependent glycoprotein that undergoes proteolytic activation by the prothrombinase complex, which consists of Factor Xa, Factor Va, calcium ions, and phospholipid membranes. Factor Xa cleaves prothrombin at Arg271 and Arg320 residues, generating the active serine protease thrombin (Factor IIa), which then cleaves fibrinopeptides A and B from fibrinogen to form fibrin monomers. Thrombin also activates platelets via PAR-1 and PAR-4 receptors and amplifies coagulation by activating Factors V, VIII, and XIII.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses evaluating bovine prothrombin as a therapeutic supplement are available in the provided research. The literature focuses exclusively on biochemical properties and structural characterization rather than clinical efficacy.

Clinical Summary

No published human clinical trials exist evaluating bovine prothrombin as a dietary or therapeutic supplement in humans. Its primary documented application is as a laboratory reagent—specifically as a PCR additive that reduces nonspecific amplification and primer dimer artifacts, a function demonstrated in in vitro molecular biology studies rather than clinical settings. The theoretical coagulation support rationale derives from bovine thrombin's well-characterized biochemistry, but direct supplementation of prothrombin has not been studied for hemostatic outcomes in human subjects. Evidence for any health benefit in humans is currently absent, and existing knowledge is extrapolated entirely from biochemical and animal research.

Nutritional Profile

Bovine Prothrombin (Bos taurus) is a single-chain glycoprotein with a molecular weight of approximately 72,000 Da (72 kDa). Protein content constitutes 100% of its dry mass as a purified protein isolate. It contains 10 carbohydrate chains accounting for approximately 8-13% of total molecular weight as N-linked glycans. Key structural domains include 10 gamma-carboxyglutamic acid (Gla) residues at the N-terminus, which are post-translationally modified and require Vitamin K as a cofactor for biosynthesis. Contains two kringle domains (Kringle 1 and Kringle 2) rich in disulfide bonds (approximately 9-10 disulfide bridges stabilizing tertiary structure). Amino acid composition is rich in glutamic acid, aspartic acid, and cysteine residues. Calcium-binding capacity is significant due to Gla residues, binding approximately 10-12 Ca2+ ions per molecule, which are essential for its conformational activation. Macronutrient contribution as a supplement is negligible given trace quantities used in laboratory applications (typically 0.1-1.0 µg/mL in PCR assays). Contains no dietary fiber, no lipids in purified form, and no measurable micronutrient content beyond bound calcium. Bioavailability for oral consumption is expected to be extremely low, as proteolytic digestion would cleave the protein into constituent amino acids, eliminating its coagulation-specific biological activity entirely.

Preparation & Dosage

No clinically studied dosage ranges are available for bovine prothrombin as a supplement or therapeutic agent. Dosing information has not been established through clinical research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

No synergistic ingredients identified due to lack of clinical research

Safety & Interactions

Bovine-derived proteins carry a theoretical risk of allergic or hypersensitivity reactions, particularly in individuals with known bovine protein allergies or sensitivities to blood-derived products. Because thrombin (the active derivative) directly promotes coagulation, bovine prothrombin supplements would be contraindicated alongside anticoagulant medications such as warfarin, heparin, direct thrombin inhibitors (dabigatran), or Factor Xa inhibitors (rivaroxaban, apixaban), as interactions could unpredictably alter clotting parameters. Individuals with hypercoagulable states, history of deep vein thrombosis, or thrombophilia should avoid prothrombin-based supplements. Safety data during pregnancy and lactation is entirely absent, and use should be avoided in these populations until evidence is established.